These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 28324032)

  • 1. Risk of Diabetes Treated in Early Adulthood After Growth Hormone Treatment of Short Stature in Childhood.
    Poidvin A; Weill A; Ecosse E; Coste J; Carel JC
    J Clin Endocrinol Metab; 2017 Apr; 102(4):1291-1298. PubMed ID: 28324032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study.
    Carel JC; Ecosse E; Landier F; Meguellati-Hakkas D; Kaguelidou F; Rey G; Coste J
    J Clin Endocrinol Metab; 2012 Feb; 97(2):416-25. PubMed ID: 22238382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study.
    Sävendahl L; Maes M; Albertsson-Wikland K; Borgström B; Carel JC; Henrard S; Speybroeck N; Thomas M; Zandwijken G; Hokken-Koelega A
    J Clin Endocrinol Metab; 2012 Feb; 97(2):E213-7. PubMed ID: 22238393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mortality in Children Receiving Growth Hormone Treatment of Growth Disorders: Data From the Genetics and Neuroendocrinology of Short Stature International Study.
    Quigley CA; Child CJ; Zimmermann AG; Rosenfeld RG; Robison LL; Blum WF
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3195-3205. PubMed ID: 28575299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age: results over 6 years.
    de Zegher F; Du Caju MV; Heinrichs C; Maes M; De Schepper J; Craen M; Vanweser K; Malvaux P; Rosenfeld RG
    J Clin Endocrinol Metab; 1999 May; 84(5):1558-61. PubMed ID: 10323379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of small for gestational age (SGA) and short stature in children born SGA who qualify for growth hormone treatment at 3 years of age: Population-based study.
    Fujita K; Nagasaka M; Iwatani S; Koda T; Kurokawa D; Yamana K; Nishida K; Taniguchi-Ikeda M; Uchino E; Shirai C; Iijima K; Morioka I
    Pediatr Int; 2016 May; 58(5):372-6. PubMed ID: 26617415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Rationale for Growth Hormone Therapy in Children with Short Stature.
    Deodati A; Cianfarani S
    J Clin Res Pediatr Endocrinol; 2017 Dec; 9(Suppl 2):23-32. PubMed ID: 29280742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short children born small for gestational age and treated with growth hormone for three years have an important catch-down five years after discontinuation of treatment.
    Fjellestad-Paulsen A; Simon D; Czernichow P
    J Clin Endocrinol Metab; 2004 Mar; 89(3):1234-9. PubMed ID: 15001616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attaining genetic height potential: Analysis of height outcomes from the ANSWER Program in children treated with growth hormone over 5 years.
    Ross JL; Lee PA; Gut R; Germak J
    Growth Horm IGF Res; 2015 Dec; 25(6):286-93. PubMed ID: 26363846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal use of growth hormone therapy for maximizing adult height in children born small for gestational age.
    Simon D; Léger J; Carel JC
    Best Pract Res Clin Endocrinol Metab; 2008 Jun; 22(3):525-37. PubMed ID: 18538291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth and growth hormone treatment in short stature children born small for gestational age.
    Labarta JI; Ruiz JA; Molina I; De Arriba A; Mayayo E; Longás AF
    Pediatr Endocrinol Rev; 2009 Feb; 6 Suppl 3():350-7. PubMed ID: 19404234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of growth hormone treatment on metabolic and cardiovascular risk factors is similar in preterm and term short, small for gestational age children.
    de Kort SW; Willemsen RH; van der Kaay DC; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):65-73. PubMed ID: 19094073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First two years' response to growth hormone treatment in very young preterm small for gestational age children.
    Garcia RA; Longui CA; Kochi C; Arruda M; Faria CD; Calliari LE; Monte O; Pachi PR; Saenger P
    Horm Res; 2009; 72(5):275-80. PubMed ID: 19844113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone regimens in Australia: analysis of the first 3 years of treatment for idiopathic growth hormone deficiency and idiopathic short stature.
    Hughes IP; Harris M; Choong CS; Ambler G; Cutfield W; Hofman P; Cowell CT; Werther G; Cotterill A; Davies PS;
    Clin Endocrinol (Oxf); 2012 Jul; 77(1):62-71. PubMed ID: 21950731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final height data, body composition and glucose metabolism in growth hormone-treated short children born small for gestational age.
    Hokken-Koelega AC; van Pareren Y; Sas T; Arends N
    Horm Res; 2003; 60 Suppl 3():113-4. PubMed ID: 14671407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac dimension and function in patients with childhood onset growth hormone deficiency, before and after growth hormone retreatment in adult age.
    Feinberg MS; Scheinowitz M; Laron Z
    Am Heart J; 2003 Mar; 145(3):549-53. PubMed ID: 12660681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone age progression during the first year of growth hormone therapy in pre-pubertal children with idiopathic growth hormone deficiency, Turner syndrome or idiopathic short stature, and in short children born small for gestational age: analysis of data from KIGS (Pfizer International Growth Database).
    Darendeliler F; Ranke MB; Bakker B; Lindberg A; Cowell CT; Albertsson-Wikland K; Reiter EO; Price DA
    Horm Res; 2005; 63(1):40-7. PubMed ID: 15627781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mortality Is Not Increased in Recombinant Human Growth Hormone-treated Patients When Adjusting for Birth Characteristics.
    Albertsson-Wikland K; Mårtensson A; Sävendahl L; Niklasson A; Bang P; Dahlgren J; Gustafsson J; Kriström B; Norgren S; Pehrsson NG; Odén A
    J Clin Endocrinol Metab; 2016 May; 101(5):2149-59. PubMed ID: 26918292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth Hormone Treatment for Short Stature in the USA, Germany and France: 15 Years of Surveillance in the Genetics and Neuroendocrinology of Short-Stature International Study (GeNeSIS).
    Pfäffle R; Land C; Schönau E; Holterhus PM; Ross JL; Piras de Oliveira C; Child CJ; Benabbad I; Jia N; Jung H; Blum WF
    Horm Res Paediatr; 2018; 90(3):169-180. PubMed ID: 30199857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Head circumference and body proportions before and during growth hormone treatment in short children who were born small for gestational age.
    Arends NJ; Boonstra VH; Hokken-Koelega AC
    Pediatrics; 2004 Sep; 114(3):683-90. PubMed ID: 15342839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.